Infection

, Volume 20, Issue 2, pp 89–93 | Cite as

Pharmacokinetics of rufloxacin once daily in patients with lower respiratory tract infections

  • R. Rimoldi
  • M. Fioretti
  • A. Albrici
  • B. P. Imbimbo
Originalia
Received:
Accepted:

Summary

The pharmacokinetic properties of rufloxacin, a new quinolone antibacterial agent, were evaluated in ten patients with lower respiratory tract infections. Patients were given 400 mg of rufloxacin once a day for seven to nine days. Plasma concentrations of the drug were determined by high-performance liquid chromatography and bioassay at regular intervals during treatment. After the first administration, maximal plasma concentrations were 3.17±0.36 mg/l (mean ± SEM) and were reached at 4.2±0.7 h. At the end of treatment peak plasma concentrations increased to 7.26±0.52 mg/l. Elimination half-life was 38.2±2.9 h, with a mean extent of accumulation of 2.96±0.30. Treatment was well tolerated, with no abnormalities noted during routine laboratory examinations. Two days after the last administration, measurable levels of rufloxacin were still observed in plasma, indicating that the long half-life of rufloxacin assures valuable antibacterial activity even after discontinuation of treatment.

Keywords

Plasma Concentration Quinolone Pharmacokinetic Property Antibacterial Agent Peak Plasma Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Pharmakokinetik von Rufloxacin bei Patienten mit tiefen Atemwegsinfektionen und einmal täglicher Gabe

Zusammenfassung

Bei zehn Patienten mit tiefen Atemwegsinfektionen wurden die pharmakokinetischen Eigenschaften von Rufloxacin, einem neuen Chinolon, untersucht. Die Patienten erhielten sieben bis zehn Tage lang einmal täglich 400 mg Rufloxacin. Während der Therapiephase wurden in regelmäßigen Abständen Messungen der Plasmakonzentrationen der Substanz mittels Hochdruckflüssigkeitchromatographie und mit Bioassay vorgenommen. Nach der ersten Dosis wurden Spitzenkonzentrationen von 3,17±0,36 mg/l (Mittelwert ± SEM) gemessen, die nach 4,2±0,7 h ereicht wurden. Am Ende der Therapiephase waren die Plasmaspitzenspiegel auf 7,26±0,52 mg/l angestiegen. Die Plasma-Eliminations-Halbwertszeit betrug 38,2±2,9 h mit einer mittleren Kumulation von 2,96±0,30. Die Therapie wurde gut vertragen, in den Routine-Laborparametern fanden sich keine Anomalien. Zwei Tage nach der letzten Dosis fanden sich im Plasma immer noch meßbare Rufloxacin-Spiegel, was zeigt, daß selbst nach Therapieende noch brauchbare Spiegel an Rufloxacin mit antibakteriellem Potential vorhanden sind.

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cecchetti, V., Fravolini, A., Fringuelli, R., Mascellani, G., Pagella, P. G., Palmioli, M., Segre, G., Terni, P. Quinolone-carboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids. J. Med. Chem. 30 (1987) 465–473.Google Scholar
  2. 2.
    Ravizzola, G., Pinsi, G., Pirali, F., Colombrita, D., Foresti, I., Peroni, L., Turano, A. Rufloxacin (MF-934):in vitro andin vivo antibacterial activity. Drugs Exp. Clin. Res. 15 (1989) 11–15.Google Scholar
  3. 3.
    Mattina, R., Cocuzza, C. E., Cesana, M., Bonfiglio, G. In vitro activity of a new quinolone, rufloxacin, against nosocomial isolates. Chemotherapy 37 (1991) 260–269.Google Scholar
  4. 4.
    Segre, G., Cerretani, D., Cerri, D., Moltoni, L. A new tricyclic fluoroquinolone, rufloxacin (MF-934), with interesting antibacterial and pharmacokinetic characteristics. Drugs Exp. Clin. Res. 14 (1988) 747–754.Google Scholar
  5. 5.
    Imbimbo, B. P., Broccali, G. P., Cesana, M., Crema, F., Parrinello Attardo, G. Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers. Antimicrob. Agents Chemother. 32 (1991) 390–393.Google Scholar
  6. 6.
    Mattina, R., Bonfiglio, G., Cocuzza, C. E., Gulisano, G., Cesana, M., Imbimbo, B. P. Pharmacokinetics of rufloxacin in healthy volunteers after repeated oral doses. Chemotherapy 37 (1991) 389–397.Google Scholar
  7. 7.
    Latteri, S., Consoli, A., Cocuzza, C., Bonfiglio, G., Imbimbo, B. P., Cesana, M., Mattina, R.: Lung tissue concentrations of rufloxacin after repeated oral administration in man. Proceedings of the 3rd International Symposium on New Quinolones. Vancouver, July 12–14, 1990. Abstract no. 345.Google Scholar
  8. 8.
    Mattina, R., Bonfiglio, G., Imbimbo, B. P., Gulisano, G., Cesana, M.: Penetration of rufloxacin into pleural and ascitic fluids in man. Proceedings of the 3rd International Symposium on New Quinolones. Vancouver, July 12–14, 1990. Abstract no. 149.Google Scholar
  9. 9.
    Boerema, J. B. J., Bach, D., Jol, C., Pahlmann, W. Penetration of rufloxacin into human prostatic tissue and fluid. J. Antimicrob. Chemother. 28 (1991) 547–554.Google Scholar
  10. 10.
    Mattina, R., Bonfiglio, G., Albrici, A., Cocuzza, G., and The Italian Multicenter UTI-Rufloxacin Group: Efficacy and safety of rufloxacin in the treatment of patients with complicated urinary tract infections. 3rd International Symposium on New Quinolones. Vancouver, July 12–14, 1990. Abstract no. 269.Google Scholar
  11. 11.
    Dirksen, M., Focht, J., Boerema, J. Rufloxacin once daily in acute exacerbations of chronic bronchitis. Infection 19 (1991) 297–300.Google Scholar
  12. 12.
    Cockcroft, D. W., Gault, M. H. Prediction of creatinine clearance from serum creatinine. Nephron 44 (1986) 66–69.Google Scholar
  13. 13.
    Robertshaw, M., Lap, K. N., Swaminathan, R. Prediction of creatinine clearance from plasma creatinine: comparison of five formulae. Br. J. Clin. Pharmacol. 28 (1989) 275–280.Google Scholar
  14. 14.
    Wagner, J. G. Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications, Hamilton 1975, pp. 102–106.Google Scholar
  15. 15.
    Heinzel, G. Salient points of various programs: TOPFIT. In:Bozler, G., van Rossum, J. M. (eds.): Pharmacokinetics during drug development: data analysis and evaluation techniques. G. Fischer Verlag, Stuttgart 1982.Google Scholar
  16. 16.
    Imbimbo, B. P., Imbimbo, E., Daniotti, S., Verotta, D., Bassotti, G. A new criterion for selection of pharmacokinetic multiexponential equations. J. Pharm. Sci. 77 (1988) 784–789.Google Scholar
  17. 17.
    Colburn, W. A. Estimating the accumulation of drugs. J. Pharm. Sci. 72 (1983) 883–834.Google Scholar
  18. 18.
    Aronson, J. K., Dengler, H. J., Dettli, L., Follath, F. Standardization of symbols in clinical pharmacology. Eur. J. Clin. Pharmacol. 35 (1988) 1–7.Google Scholar
  19. 19.
    Gibaldi, M., Levy, G., McNamara, P. J. Effect of plasma protein and tissue binding on the biologic half-life of drugs. Clin. Pharmacol. Ther. 24 (1978) 1–4.Google Scholar
  20. 20.
    Wise, R., Johnson, J., O'Sullivan, N., Andrews, J. M., Imbimbo, B. P. Pharmacokineties and tissue penetration of rufloxacin, a long-acting quinolone antimicrobial. J. Antimicrob. Chemother. 28 (1991) 905–909.Google Scholar
  21. 21.
    Kisicki, J., Griess, R. S., Ott, C. L., McCormak, R. J., Troetel, W., Imbimbo, B. P.: Pharmacokinetics of rufloxacin in healthy volunteers after repeated oral doses. Proceedings of the 17th International Congress of Chemotherapy. Berlin, June 23–27, 1991. Abstract no. 379.Google Scholar

Copyright information

© MMV Medizin Verlag GmbH München 1992

Authors and Affiliations

  • R. Rimoldi
    • 1
  • M. Fioretti
    • 1
  • A. Albrici
    • 2
  • B. P. Imbimbo
    • 2
  1. 1.Dept. of PneumologyVarese HospitalVarese
  2. 2.Medical Dept.Mediolanum FarmaceuticiTrezzano S/N Colombo (Milan)Italy

Personalised recommendations